AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 JUN 27 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - Vaccination against influenza cannot be justified in cost-benefit terms in Hong Kong, even when only the elderly get the vaccine, say researchers working there.
Their findings challenge recent studies that have touted the cost effectiveness of the influenza vaccine in other areas of the world.
"These studies did not examine the situation in southern China, a hypothetical influenza epicenter for the emergence of pandemic influenza viruses," pointed out K.A. Fitzner and colleagues
They collected surveillance data in Hong Kong in 1993-1994 and estimated the social and medical costs of influenza-like illness (ILI) compared with the cost of vaccination.
In this mild influenza year, their model estimated the ILI incidence to be 110/1,000. ILI was most common in people younger than 25 but most severe in the elderly, reported Fitzner and coworkers.
A nonepidemic year in which influenza B predominates would lead to more than 660,000 cases in this population, the researchers predicted, with a cost of HK$283/case (US$36) versus a cost of HK$74 (US$9.50) per vaccinated individual ("Cost-effectiveness study on influenza prevention in Hong Kong," Health Policy, June 2001;56(3):215-234).
Source: HighBeam Research, Assuming Vaccine Is Cost-Effective Is Not Necessarily Valid In Hong...